文献速递眼底病与葡萄膜炎

视网膜静脉阻塞继发黄斑水肿患者按需注射雷珠单抗频率的预测因素

Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion.
PubMed 文献 · Am J Ophthalmol · 2023-01-14

该研究为前瞻性多中心SHORE试验的事后分析,纳入95例视网膜静脉阻塞继发黄斑水肿患者,接受7次每月雷珠单抗注射后转为按需或每月注射。多变量回归显示,基线视网膜内层结构紊乱程度更大(β=0.021,P=.0275)和第3个月中心亚区厚度更高(β=0.01,P<.001)与按需注射总次数更多相关。

要点

  • 基线视网膜内层结构紊乱程度更大与按需雷珠单抗注射次数更多相关(β=0.021,P=.0275)。
  • 第3个月中心亚区厚度更高与按需雷珠单抗注射次数更多相关(β=0.01,P<.001)。
  • 按需阶段平均注射次数为4.32次(SD,2.35)。

核心结论

  • 基线视网膜内层结构紊乱程度更大和开始雷珠单抗治疗后第3个月中心亚区厚度更高,与视网膜静脉阻塞继发黄斑水肿按需治疗患者更频繁的雷珠单抗注射相关。

研究设计与样本

  • 前瞻性多中心SHORE研究的事后分析,纳入95例视网膜静脉阻塞继发黄斑水肿患眼,接受7次每月雷珠单抗注射后,第7至15个月接受按需注射或非随机每月注射。

主要发现

  • 患者平均年龄65.3岁(SD,12.7)。
  • 57.9%为分支视网膜静脉阻塞/半侧视网膜静脉阻塞,42.1%患眼为中心视网膜静脉阻塞。
  • 7个月固定给药期间平均最佳矫正视力改善+17.5个早期治疗糖尿病视网膜病变研究(ETDRS)字母(SD,1.2)。
  • 第7至15个月按需阶段平均最佳矫正视力较基线稳定(+20.1个ETDRS字母,SD,1.5)。
  • 按需注射平均次数为4.32次(SD,2.35)。

关键数值与推荐

  • 多变量回归中,基线视网膜内层结构紊乱程度更大与按需注射总次数更多相关(β=0.021,P=.0275)。
  • 多变量回归中,第3个月中心亚区厚度更高与按需注射总次数更多相关(β=0.01,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate spectral-domain optical coherence tomography (SD-OCT) biomarkers associated with ranibizumab injection frequency after 7 monthly doses in the prospective, multicenter SHORE study for macular edema due to retinal vein occlusion (RVO). DESIGN: Prospective phase IV clinical trial data. METHODS: Post hoc analysis of 95 patients who received 7 monthly doses of ranibizumab followed by either pro re nata (PRN) or nonrandomized monthly injections from months 7-15 in eyes with macular edema secondary to RVO. Baseline SD-OCT biomarkers assessed include central subfield thickness (CST), epiretinal membrane presence, intraretinal and subretinal fluid, hyperreflective foci, disorganization of retinal inner layers (DRIL), and disruption of the external limiting membrane, ellipsoid zone, or interdigitation zone. Univariate and multivariable regression analyses evaluated the association between SD-OCT biomarkers and ranibizumab injection frequency. RESULTS: Mean age of patients was 65.3 (SD, 12.7) years. Overall, 57.9% had BRVO/HRVO and 42.1% of eyes had CRVO. Mean BCVA improved (+17.5 [SD, 1.2] Early Treatment of Diabetic Retinopathy Study [ETDRS] letters) during the 7-month fixed dosing period, remaining stable from baseline (+20.1 [SD, 1.5] ETDRS letters) during the PRN phase from months 7-15. The mean number of PRN injections was 4.32 (SD, 2.35). On multivariate regression, greater baseline DRIL (β = 0.021, P = .0275) and higher CST at month 3 (β = 0.01, P < .001) were associated with a higher total number of PRN injections. CONCLUSION: Greater baseline DRIL and higher CST at 3 months after starting ranibizumab treatment are associated with more frequent ranibizumab injections in PRN-treated patients with macular edema due to RVO.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yiu G, Huang D, Wang Y, et al. Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion. Am J Ophthalmol. 2023. PMID: 36646240. doi:10.1016/j.ajo.2023.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。